Session » Abstracts: Osteoarthritis – Clinical Trials

Date: Saturday, November 16, 2024

Time: 1:00PM-2:30PM

Meeting: ACR Convergence 2024

1:00PM-2:30PM: Abstract Number: 0789

An Online Trial to Assess the Efficacy and Safety of a Supplement Combination in People with Hand Osteoarthritis

1:00PM-2:30PM: Abstract Number: 0790

CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study

1:00PM-2:30PM: Abstract Number: 0787

Efficacy of Intra-Articular Hyaluronic Acid Injection for Nonsurgical Management of Carpometacarpal Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

1:00PM-2:30PM: Abstract Number: 0788

Long-term Effectiveness of a Lifestyle Intervention for Osteoarthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial

1:00PM-2:30PM: Abstract Number: 0791

Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset

1:00PM-2:30PM: Abstract Number: 0792

Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].